These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
267 related items for PubMed ID: 11592386
1. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ. Arthritis Rheum; 2001 Sep; 44(9):2201-10. PubMed ID: 11592386 [Abstract] [Full Text] [Related]
3. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. Frith JC, Rogers MJ. J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397 [Abstract] [Full Text] [Related]
8. The cellular uptake and metabolism of clodronate in RAW 264 macrophages. Mönkkönen H, Rogers MJ, Makkonen N, Niva S, Auriola S, Mönkkönen J. Pharm Res; 2001 Nov; 18(11):1550-5. PubMed ID: 11758762 [Abstract] [Full Text] [Related]
9. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Proc Natl Acad Sci U S A; 1999 Jan 05; 96(1):133-8. PubMed ID: 9874784 [Abstract] [Full Text] [Related]
10. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Räikkönen J, Crockett JC, Rogers MJ, Mönkkönen H, Auriola S, Mönkkönen J. Br J Pharmacol; 2009 Jun 05; 157(3):427-35. PubMed ID: 19371349 [Abstract] [Full Text] [Related]
11. The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron. Mönkkönen J, Heath TD. Calcif Tissue Int; 1993 Aug 05; 53(2):139-46. PubMed ID: 8402323 [Abstract] [Full Text] [Related]
15. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Sutherland KA, Rogers HL, Tosh D, Rogers MJ. Arthritis Res Ther; 2009 Jan 05; 11(2):R58. PubMed ID: 19405951 [Abstract] [Full Text] [Related]
16. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases. Schem C, Tower RJ, Kneissl P, Rambow AC, Campbell GM, Desel C, Damm T, Heilmann T, Fuchs S, Zuhayra M, Trauzold A, Glüer CC, Schott S, Tiwari S. J Bone Miner Res; 2017 Mar 05; 32(3):536-548. PubMed ID: 27714838 [Abstract] [Full Text] [Related]
18. Effects of liposome-encapsulated clodronate on chlorhexidine gluconate-induced peritoneal fibrosis in rats. Kushiyama T, Oda T, Yamada M, Higashi K, Yamamoto K, Oshima N, Sakurai Y, Miura S, Kumagai H. Nephrol Dial Transplant; 2011 Oct 05; 26(10):3143-54. PubMed ID: 21362737 [Abstract] [Full Text] [Related]
19. Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro. Naito M, Nagai H, Kawano S, Umezu H, Zhu H, Moriyama H, Yamamoto T, Takatsuka H, Takei Y. J Leukoc Biol; 1996 Sep 05; 60(3):337-44. PubMed ID: 8830790 [Abstract] [Full Text] [Related]
20. Periarticular bone alterations in chronic antigen-induced arthritis: free and liposome-encapsulated clodronate prevent loss of bone mass in the secondary spongiosa. Oelzner P, Bräuer R, Henzgen S, Thoss K, Wünsche B, Hersmann G, Abendroth K, Kinne RW. Clin Immunol; 1999 Jan 05; 90(1):79-88. PubMed ID: 9884355 [Abstract] [Full Text] [Related] Page: [Next] [New Search]